dr. leora horn on toxicities with immunotherapy in lung cancer
Published 7 years ago • 276 plays • Length 0:51Download video MP4
Download video MP3
Similar videos
-
4:03
managing toxicity in immunotherapy for lung cancer
-
1:51
dr. horn on selecting inhibitors for alk nsclc
-
1:00:44
practical application of recent clinical data for immunotherapy in nsclc
-
1:22
dr. horn on updated data from impower133 in small cell lung cancer
-
7:49
immunotherapy in nsclc: audience q&a
-
1:08
dr. horn on the fda approval of atezolizumab plus bevacizumab and chemotherapy in nsclc
-
4:15
the toxicities associated with immunotherapy in lung cancer patients
-
1:37
dr. horn on incorporating t790m-mutant nsclc agents into nccn guidelines
-
1:07
dr. horn on the role of mobocertinib in nsclc
-
8:36
researcher comment: the teravolt findings | leora horn
-
7:41
asco 2019: dr. horn highlights progress in lung cancer
-
1:08
toxicities of immunotherapy and patient expectations in lung cancer
-
1:11
dr. lopes on the rationale to stop immunotherapy after 2 years in lung cancer
-
5:16
immunotherapy and brain metastatic lung cancer
-
2:51
are immune checkpoint inhibitors sufficiently tolerable to recommend them for older patients?
-
19:31
panel q&a session on acquired resistance with drs. riely & horn
-
4:06
shine a light 2015 dr. leora horn
-
5:58
how long to continue immunotherapy
-
4:03
managing pneumonitis in nsclc